TROP-2: A clinically and commercially validated cancer target
13 Jan 2024
ImmunotherapyDrug ApprovalAccelerated ApprovalClinical Study
BARCELONA, Spain I January 13, 2024 I La Merie Publishing released its newest product reviewing the pipeline of anti-TROP-2 immunotherapeutics on the market and in R&D:
TROP-2-Targeted Immunotherapy Pipeline Review
Target: TROP-2; trophoblast antigen 2; epithelial glycoprotein-1 (EGP-1)
Product Category: Antibody; Cells; mRNA
This product provides basic information on immunotherapeutics on the market and in R&D targeting TROP-2.
This product consists of:
This product is delivered on the very same day of purchase by e-mail containing competitor and project history reports in pdf format and database credentials. Reports are prepared on the same day.
The transmembrane glycoprotein Trop-2 is highly expressed in many cancers, but not all, and has differential expression in certain normal tissues. Trop-2 is also known as trophoblast antigen 2, cell surface glycoprotein Trop2, gastrointestinal tumor-associated antigen GA7331, pancreatic carcinoma marker protein GA733-1, membrane component chromosome 1 surface marker 1 M1S1, epithelial glycoprotein-1, EGP-1, CAA1, Gelatinous Drop-Like Corneal Dystrophy GDLD, and TTD2. It is coded by the gene Tacstd2. It is about 35 kDa. Trop2 spans the cellular membrane: it has an extracellular, a transmembrane, and an intracellular domain, along with a cytoplasmic tail essential for signaling.
Trodelvy® (sacituzumab govitecan-hziy) is a first-in-class Trop-2 directed antibody-drug conjugate. Trodelvy is intentionally designed with a proprietary hydrolyzable linker attached to SN-38, a topoisomerase I inhibitor payload. This unique combination delivers potent activity to both Trop-2 expressing cells and the microenvironment.
Trodelvy is approved in almost 50 countries, with multiple additional regulatory reviews underway worldwide, for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. In the U.S., Trodelvy also has accelerated approval for treatment of certain patients with second-line metastatic urothelial cancer (UC); see below for the full U.S. indication for Trodelvy.
With 2022 sales of US$ 680 mln (+79% vs previous year), Trodelvy is on the way to become a blockbuster biologic.
This clinical and commercial success of Trodelvy has attracted many followers applying their proprietary drug modality technologies to generate next generation TROP2-targeted immunotherapy candidates.
The report “TROP-2-Targeted Immunotherapy Pipeline Review” can be acquired at La Merie Publishing’s online store: https://lamerie.com/report/trop-2-targeted-immunotherapy-pipeline-review/
About La Merie Publishing
La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports. La Merie Publishing products can be purchased in the online store www.lamerie.com and from selected Resellers.
La Merie Publishing offers the service of custom report preparation for corporate clients, including, but not limited to, pipeline analysis reports, drug profiles and any other competitive intelligence elaboration of interest.
SOURCE: La Merie Publishing
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
-Targets
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.